South Korea
· Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 495.51 billion. The enterprise value is 475.96 billion.
| Market Cap | 495.51B |
| Enterprise Value | 475.96B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 10.54 million shares outstanding. The number of shares has increased by 14.24% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 10.54M |
| Shares Change (YoY) | +14.24% |
| Shares Change (QoQ) | +8.23% |
| Owned by Insiders (%) | 21.17% |
| Owned by Institutions (%) | 0.12% |
| Float | 4.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 56.41 |
| PB Ratio | 7.52 |
| P/TBV Ratio | 19.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.43 |
| EV / Sales | 58.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.09 |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.11 |
| Quick Ratio | 3.66 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | -34.69 |
Financial Efficiency
Return on equity (ROE) is -29.50% and return on invested capital (ROIC) is -18.64%.
| Return on Equity (ROE) | -29.50% |
| Return on Assets (ROA) | -15.14% |
| Return on Capital (ROIC) | -18.64% |
| Revenue Per Employee | 389.85M |
| Profits Per Employee | -891.31M |
| Employee Count | 21 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 42,491.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 58.28 |
| Average Volume (20 Days) | 342,552 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 8.19 billion and -18.72 billion in losses. Loss per share was -1,905.21.
| Revenue | 8.19B |
| Gross Profit | 8.17B |
| Operating Income | -22.14B |
| Pretax Income | -20.09B |
| Net Income | -18.72B |
| EBITDA | -16.92B |
| EBIT | -22.14B |
| Loss Per Share | -1,905.21 |
Balance Sheet
The company has 37.76 billion in cash and 9.42 billion in debt, giving a net cash position of 28.34 billion or 2,688.35 per share.
| Cash & Cash Equivalents | 37.76B |
| Total Debt | 9.42B |
| Net Cash | 28.34B |
| Net Cash Per Share | 2,688.35 |
| Equity (Book Value) | 74.69B |
| Book Value Per Share | 6,252.59 |
| Working Capital | 33.51B |
Cash Flow
In the last 12 months, operating cash flow was -15.55 billion and capital expenditures -267.61 million, giving a free cash flow of -15.82 billion.
| Operating Cash Flow | -15.55B |
| Capital Expenditures | -267.61M |
| Free Cash Flow | -15.82B |
| FCF Per Share | -1,500.47 |
Margins
Gross margin is 99.80%, with operating and profit margins of -270.38% and -228.63%.
| Gross Margin | 99.80% |
| Operating Margin | -270.38% |
| Pretax Margin | -245.44% |
| Profit Margin | -228.63% |
| EBITDA Margin | -206.73% |
| EBIT Margin | -270.38% |
| FCF Margin | n/a |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.24% |
| Shareholder Yield | -14.24% |
| Earnings Yield | -4.05% |
| FCF Yield | -3.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
D&D Pharmatech has an Altman Z-Score of 3.27.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | n/a |